Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Postprint
DOI
PMC
 |
Open Access Green |
as soon as is submitted to ZB.
Targeting pancreatic β cells for diabetes treatment.
Nat. Metab. 4, 1097-1108 (2022)
Insulin is a life-saving drug for patients with type 1 diabetes; however, even today, no pharmacotherapy can prevent the loss or dysfunction of pancreatic insulin-producing β cells to stop or reverse disease progression. Thus, pancreatic β cells have been a main focus for cell-replacement and regenerative therapies as a curative treatment for diabetes. In this Review, we highlight recent advances toward the development of diabetes therapies that target β cells to enhance proliferation, redifferentiation and protection from cell death and/or enable selective killing of senescent β cells. We describe currently available therapies and their mode of action, as well as insufficiencies of glucagon-like peptide 1 (GLP-1) and insulin therapies. We discuss and summarize data collected over the last decades that support the notion that pharmacological targeting of β cell insulin signalling might protect and/or regenerate β cells as an improved treatment of patients with diabetes.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
ISSN (print) / ISBN
2522-5812
e-ISSN
2522-5812
Journal
Nature metabolism
Quellenangaben
Volume: 4,
Issue: 9,
Pages: 1097-1108
Publisher
Springer
Publishing Place
London
Non-patent literature
Publications
Reviewing status
Peer reviewed